Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Digital Health Trends 2024 - Implications for Research and Patient Care

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE

Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
IQVIA Careers
Featured Careers
Stay Connected

WE'RE HIRING

"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.

VIEW ROLES
MAIN/Contact Us
Contact Us/
Institute Report
Assessing the Biosimilar Void in the U.S.
Achieving Sustainable Levels of Biosimilar Competition
Feb 03, 2025
To download files you must give consent to process your personal data by clicking the "Accept" button below.

Biologic medicines are becoming a mainstay in disease treatment and represent a growing share of medicine spending. Biosimilars have provided savings to the U.S. healthcare system and increased patient access to these disease-modifying therapies. However, biosimilar competition is not guaranteed. Existing challenges to the biosimilar market and increasing complexity of biologic medicines could limit biosimilar development in the future and diminish the benefits realized from biosimilar competition. Understanding and addressing the potential ‘biosimilar void’ is crucial for the future sustainability of the biosimilar market and to realize the cost savings these medicines bring.

In this report, patent expiries were assessed for all biologic medicines on the U.S. market. The current status of biosimilar development was collated and overlayed with patent expiries occurring over the next decade from 2025 to 2034. We looked at a range of characteristics of biologic medicines that could limit biosimilar development and contribute to a ‘biosimilar void’—or areas where biosimilar competition may not transpire. Factors limiting the biosimilar pipeline include sales potential, timing of patent expiry, therapeutic area, orphan status, and molecule complexity. This report characterizes this biosimilar void and provides potential solutions for stakeholders to maximize biosimilar opportunity. Biosimilar competition provides cost savings and plays a vital role in the overall sustainability of the U.S. healthcare system. Understanding and addressing the biosimilar void is critical to realize the benefits these medicines bring.

Key findings

  • Over the next decade (2025–2034), 118 biologics are expected to lose patent protection, presenting a $232Bn opportunity for biosimilars.
  • Only 12 molecules set to lose patent protection from 2025 to 2034 have biosimilars in development as of June 2024, with the remaining 106 biologic patent expiries representing a ‘biosimilar void.’
  • Factors influencing biosimilar development are market potential, timing of patent expiry, disease area, patient population size, and complexity of manufacturing and clinical testing.
  • To ensure the sustainability of the biosimilar market and the savings and affordability benefits are fully realized by the healthcare system and patients, stakeholders must address the challenges contributing to a biosimilar void.

Other findings:


Number of biologics and sales exposure by year of expiry in U.S., 2025-2034

  • The next decade presents significant opportunity for biosimilars as 118 biologics are expected to lose patent protection from 2025 to 2034, with loss of exclusivity (LoE) opportunities for these biologics totaling $234Bn.
  • Average sales exposure per year over the next decade is $23Bn and 12 biologics losing patent protection on average each year, compared to $9Bn over the last decade and five expiries highlighting the accelerating pace of patent expiries in biologics.
  • Looking at historic patent expiries shows that biosimilar competition is not a certainty for all biologics, and increasing pressures on biosimilar developers may limit the future potential of biosimilars.


Share of biologics by pre-expiry sales and number of biosimilars in development, expiries 2025-2034

  • Of the 118 biologic patent expiries over the next decade, 10% currently have biosimilars in development and could face competition, while 90% have no pipeline limiting savings potential to the healthcare system.
  • Biosimilar development is concentrated in biologics with high sales potential and near-term expiries.
  • Thirteen high sales, near term expiries have no biosimilar development, indicating that sales and expiry timing are not the only factors influencing biosimilar developer decision-making.


Biologic expiries by orphan status and biosimilar pipeline, 2025-2034

  • Of the upcoming patent expiries, 64% (75) have been approved for orphan indications, of which the majority are approved only for rare diseases (orphan only) and not for both rare diseases and larger population diseases (partial orphan).
  • Orphan only biologics have little biosimilar development given the clinical development complexities and often low sales potential; 27% of partial orphan drugs have a biosimilar pipeline.
  • Other factors influencing biosimilar development are disease area and complexity of manufacturing and clinical testing.


Challenges for biosimilar sustainability

  • Factors limiting biosimilar development include burdensome regulatory requirements, slow market adoption, high investment costs, confusion over interchangeability, reimbursement challenges, and uncertainty related to the Inflation Reduction Act.
  • Potential solutions to ensure sustainability of biosimilar competition include regulatory streamlining, improving market conditions for biosimilars, and collaboration among stakeholders.
  • In an ideal market, if all products facing patent expiries in the next 10 years that currently have no biosimilar pipeline were to face biosimilar competition at expiry, the U.S. healthcare system could save an additional $189Bn on top of savings generated by biosimilars already on the market or expected to enter.

Related solutions

Biosimilars

Bring your biosimilar to market faster by tapping into unparalleled data, technology, advanced analytics, and scientific expertise.

Clinical Research & Development Solutions

Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.

Contact Us